Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 2/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.59 |
| ▸ | TFPI | P10646 | 4/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 5/20 | 0.56 |
| ▸ | NPY4R | P50391 | 5/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.56 |
| ▸ | NPY1R | P25929 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31674472 | 0.95 | EPHA2 (0.61) | EPHA2OPRM1OPRK1TFPICXCR4 | |
| SCHEMBL31674456 | 0.93 | OPRM1 (0.62) | EPHA2OPRM1OPRK1 | |
| SCHEMBL30607473 | 0.92 | NPY2R (0.63) | EPHA2TFPINPY2RNPY4RNPY5R | |
| SCHEMBL31741322 | 0.90 | EPHA2 (0.66) | EPHA2OPRM1TFPINPY2RNPY4R | |
| SCHEMBL31674468 | 0.88 | OPRM1 (0.58) | EPHA2OPRM1OPRK1 | |
| SCHEMBL30932611 | 0.87 | EPHA2 (0.59) | EPHA2OPRM1OPRK1CXCR4 | |
| SCHEMBL31356488 | 0.87 | EPHA2 (0.58) | EPHA2OPRM1OPRK1 | |
| SCHEMBL30415361 | 0.87 | EPHA2 (0.65) | EPHA2TFPICXCR4NPY2RNPY4R | |
| SCHEMBL30903277 | 0.87 | C5AR1 (0.65) | EPHA2TFPICXCR4 | |
| SCHEMBL30640887 | 0.86 | NPY2R (0.64) | EPHA2TFPICXCR4NPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340916-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12391971-B2 | Method for synthesizing peptides in cell-free translation system | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391971-B2 | Method for synthesizing peptides in cell-free translation system | AARS1, NSUN3, RNGTT | EPHA2 3364/4885OPRM1 4491/4885OPRK1 3415/4885 |
| US-20250340916-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | AARS1, NSUN3, RNGTT | EPHA2 3364/4885OPRM1 4491/4885OPRK1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.